---
title: "Weekly Recap | IBB.US -2.16%, underperforming the S&P 500"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297392864.md"
description: "IBB.US closed the week down 2.16% at $208.95, underperforming the S&P 500 by about 2.65 percentage points. The ETF started Monday near $212.695, pushed to a weekly high of $217.12 on Tuesday, then faded across the next three sessions to finish near the weekly low of $208.54. The weekly range was 4.03%, and average daily volume of 1.36 million shares came in about 11.25% below the median."
datetime: "2026-08-29T07:08:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297392864.md)
  - [en](https://longbridge.com/en/news/297392864.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297392864.md)
generator: "portal-rs"
---

# Weekly Recap | IBB.US -2.16%, underperforming the S&P 500

## The Week

IBB.US closed the week down 2.16% at $208.95, underperforming the S&P 500 by about 2.65 percentage points. The ETF started Monday near $212.695, pushed to a weekly high of $217.12 on Tuesday, then faded across the next three sessions to finish near the weekly low of $208.54. The weekly range was 4.03%, and average daily volume of 1.36 million shares came in about 11.25% below the median.

## Sector News

Biotech news this week centred on individual company events and regulatory updates. Gilead’s Trodelvy gained an expanded EU indication for first-line metastatic triple-negative breast cancer, and the FDA approved its once-daily HIV single-tablet regimen. Amgen’s Tezspire met primary endpoints in a Phase 3 eosinophilic esophagitis trial. Revolution Medicines’ pancreatic cancer drug approval drew analyst target-price increases. On the other side, Regeneron and Illumina saw director share sales or class-action news. At the ETF level, iShares Trust filed only periodic disclosures: NPORT-P and N-PX.

## The Week Ahead

Next week brings a busy macro calendar: the Dallas Fed manufacturing index on Monday, followed by S&P Global manufacturing PMI final, ISM manufacturing PMI, and JOLTS job openings on Tuesday, then ADP employment, factory orders, and EIA crude inventories on Wednesday. These prints will test how the market prices rates and growth expectations, which can feed into biotech valuations and liquidity conditions.

## In Short

IBB.US fell more than the broad market this week against a mixed backdrop of single-stock news. The latest trading day showed large-lot money as a net seller. Within the sector, pockets of drug approvals and clinical data sat alongside director selling and litigation noise, leaving the tape split rather than directional. The focus now is whether macro data keeps pressure on rate-sensitive assets and how the sector’s internal divergence evolves.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)

## Related News & Research

- [Oncopeptides earns EANO poster nod as PDC platform pushes into glioblastoma](https://longbridge.com/en/news/299726078.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [BOI: Revenue and profit fell sharply, with only North America and other countries showing growth](https://longbridge.com/en/news/299345493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**